Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Google Inc (GOOG) vs Viatris Inc (VTRS) Price & Performance

Google IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Google Inc vs Viatris Inc — how do they compare? Google Inc trades at $355.03 (market cap $4.52T), while Viatris Inc trades at $16.6 (market cap $19.44B). The key difference: Google Inc is far larger — about 232.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.

GOOGVTRS
Market Cap
$4.52T$19.44B
Volume
1,511,127
Sector
TechnologyHealth
52-Week High
$399.06$17.39
52-Week Low
$183.77$8.74
Enterprise Value
$4.49T$31.65B
Dividend Yield
0.24%2.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $370.43, up 3.67% on the day, with strong bullish momentum from recent earnings beats and a consensus analyst price target of $457.50. The stock shows robust fundamentals with 2025 revenue of $402.84B, net income margin of 37.92%, and consistent cash flow growth. Technical indicators are bullish, with the current price near resistance at $374, while sentiment is positive due to Warren Buffett's recent endorsement and AI-driven growth prospects.

Outlook remains favorable with earnings growth and AI expansion as key catalysts, though regulatory risks and market volatility pose challenges. The stock offers upside potential aligned with analyst targets, supported by high institutional ownership and strong profitability metrics.

Viatris Inc

Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.

The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS